You are here

SU2C-SARC032-SPORE05

Active
SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab
Type of Sarcoma: 
Soft Tissue Sarcoma of the Extremity
Drug: 
Pembrolizumab
Accrual Status: 
Not Yet Open
Overall Study Principal Investigator: 
David Kirsch, MD, PhD
Professor, Radiation Oncology / Professor of Pharmacology and Cell Biology
Duke University

For more information about this trial and open sites: